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Factors that regulate the growth and development of primitive bone marrow stromal cell precursors are not well defined. We have examined 25 purified recombinant growth factors for their ability to initiate and support clonogenic growth of fibroblast colony-forming cells (CFU-F) from adult human bone marrow. Assays were performed using bone marrow mononuclear cells (BMMNC) enriched in CFU-F by magnetic-activated cell sorting (MACS) using the monoclonal antibody (MoAb) STRO-1. A serum-deprived assay was developed to avoid components of fetal calf serum (FCS) that may mask or otherwise modify the response of CFU-F to exogenously added factors. L-ascorbate and the glucocorticoid dexamethasone were found to be essential for CFU-F colony development under serum-deprived conditions. Importantly, clonogenic growth of CFU-F in this culture system was absolutely dependent on an exogenous source of growth factor. Platelet-derived growth factor-BB (PDGF) and epidermal growth factor (EGF) demonstrated the greatest ability to support colony growth. Colony formation was dose-dependent, with half-maximal colony numbers at approximately 0.2 ng/mL for either factor and pla-EMATOPOIESIS in vivo occurs in association with a complex stromal tissue that consists of a phenotypically heterogeneous population of vascular and connective tissue-type cells, including smooth muscle cells, reticular cells, adipocytes, osteoblasts, and a number of different types of vascular endothelial celIs.l4 A similarly diverse population of stromal elements develops in vitro when bone marrow cells are cultured under appropriate condition^.^-^ Given the heterogeneous composition of the stromal microenvironment of the bone marrow and the well-documented capacity of this tissue for regeneration after a variety of proceedures,"." these data raise the question as to whether each of the various stromal cell types is a self-maintaining population within the bone marrow or, alternatively, arises from a population of stromal cell precursors with the capacity to give rise to each of the above-mentioned components of the marrow s t r~m a . '~* l~ Putative stromal cell precursors have been identified in bone marrow from a variety of species, including humans, by their ability to generate from single-cell suspensions of bone marrow colonies of fibroblast-like cells originating from single clonogenic progenitors termed fibroblast colonyforming cells (CFU-F),I4"' In support of the stromal stem cell hypothesis proposed by Owen" and Owen and Freidenstein,'2.13 studies involving the ectopic transplantation of individual colonies in mice have shown that a minor proportion of CFU-F demonstrate the capacity to develop into marrow organs containing the full spectrum of stromal elements listed above."
In contrast with hematopoietic progenitors whose growth requirements and responses to a wide variety of growth factors have been studied in great detail,"-" little is known about the growth requirements of stromal precursors ( c m -F) in vitro. In the studies performed to date, interpretation of the data is complicated by the fact that, for the most part, unfractionated bone marrow cell populations were used teau numbers at concentrations in excess of 1.0 ng/mL. Simultaneous addition of PDGF and EGF had no effect on the number of colonies initiated but resulted in dose-dependent increases in mean colony diameter that were significant (P S .05) when compared with the effect of either factor alone or with the size of colonies elicited in control cultures by 20% FCS. Fluorescence-activated cell sorting (FACS) of BMMNC using MoAbs to the alpha chain of the PDGF receptor and to the EGF receptor in combination with the Moab STRO-1 demonstrated constitutive expression of both receptors by greater than 90% on CFU-F. Receptors for insulin-like growth factor-l (IGF-l) and nerve growth factor (NGF) were also detected on STRO-l+ CFU-F, but in vitro both IGF-l and NGF did not support colony growth. This report demonstrates the development of a simple, reproducible, and stringent culture system for the growth and assay of stromal precursors under serum-deprived conditions and represents an important prerequisite for future studies of the role of growth factors in the regulation of stromal cell proliferation, differentiation, and development. 0 1995 by The American Society of Hematology.
without any attempt to remove accessory ~e l l s .~~~~' Moreover, CFU-F assays were performed in the presence of fetal calf serum (FCS), which may mask or modify the response of C m -F to exogenously added factors.
In the present study, we have attempted to circumvent these problems by performing C m -F assays using cells selected for STRO-1 antigen expression. Previous studies have shown that monoclonal antibody (MoAb) STRO-1 identifies a minor proportion of human bone marrow cells that is devoid of accessory cells but includes essentially all detectable CFU-F. 9 .28 In addition, we have developed an in vitro culture assay for CFU-F under serum-deprived conditions. Under these circumstances, CFU-F demonstrate an absolute requirement for exogenous cytokines to initiate and support clonal growth and development. Using this assay, we examined the growth requirements of CFU-F in vitro.
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after informed consent was obtained according to procedures approved by the Ethics Committee of the Royal Adelaide Hospital (Adelaide, Australia). Low-density bone marrow mononuclear cells (BMMNC) were isolated by density centrifugation over Ficoll (Lymphoprep; Nycomed, Oslo, Norway).
Cytokines. The following cytokines were used: recombinant human (rh) basic fibroblast growth factor (bFGF GIBCO BRL, Gaithersburg, MD); purified mouse epidermal growth factor (EGF; Sigma, St Louis, MO); rh-long R' insulin-like growth factor-1 (IGF-I ; Gro Pep Pty Ltd, Adelaide, Australia); rh-platelet-derived growth factor-BB (PDGF), interleukin-1 beta (IL-IP), tumor necrosis factor-alpha (TNFa), vascular endothelial cell growth factor (VEGF), and stem cell factor (SCF; Pepro Tech Inc, Rocky Hill, NJ); rhIL-3, IL-6, IL-9, 1L-l I, granulocyte-macrophage colony-stimulating factor (GM-CSF), M-CSF, transforming growth factor beta (TGFP), macrophage inflammitory protein-1 alpha (MIP-I a), leukemia inhibitory factor (LIF), and bone morphogenic protein-2 (BMP-2; donated by Dr Steve Clark, Genetics Institute, Cambridge, MA); rhlL-4, IL-7, and interferon y (1FN-y; Genzyme Corp, Cambridge, MA); rhG-CSF (R&D Systems, Minneapolis, MN); rhIL-8 (Dr W. Smith, Human Immunology, Hanson Centre for Cancer Research, Adelaide, Australia); rhIFNa-2a (F. Hoffman-LaRoche and CO, Ltd, Basel, Switzerland); and purified mouse nerve growth factor (NGF; donated by Dr B. Rush, Flinders Medical Centre, Adelaide, Australia).
MoAbs. The following MoAbs were used throughout the course of this study. STRO-I (mouse IgM anti-human bone marrow stromal cells) was used in the form of undiluted tissue culture supernatant maintained in serum-free culture (Nutridoma NS; Boehringer Mannheim, Germany). Tissue culture supernatants containing the antibodies 1 A6.12 (anti-salmonella; IgM-negative control), 3D3 (anti-salmonella; IgG,-negative control), and YB5.B8 (anti-human c-kit, Isolation qf STRO-I' cells by magnetic-activated cell sorting (MACS). This procedure has been described previously." Briefly, BMMNC (1 X lo8 cells) were suspended in 2 mL of STRO-1 supernatant in a 5-mL polypropylene tube and placed on a rotator for 60 minutes at 4°C. The cells were then washed twice in Hanks' buffered saline solution (HBSS) supplemented with 1% bovine serum albumin (BSA: Cohn fraction V; Sigma) and resuspended in I mL of buffer containing a 1/50 dilution of biotinylated goat antimouse IgM (p-chain specific; Southern Biotechnology Associates, Birmingham, AL) for 45 minutes at 4°C. The cells were washed three times in MACS buffer (comprising single strength Ca*+-and Mn2'-free phosphate-buffered saline (PBS) supplemented with 1% BSA, 5 mmol/L EDTA, and 0.01 % sodium azide) and resuspended in 900 pL of MACS buffer to which 100 pL of streptavidin microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) was added. After incubating for 15 minutes at 4°C. streptavidin-phycoerythrin (PE) conjugate ( M O ; Caltag Laboratories, San Francisco, CA) was added directly to the same cell suspension for an additional 5 minutes. After washing twice in MACS buffer, a small aliquot of cells was removed for flow cytometric analysis. The remaining cells were separated on a magnetic stainless steel wool column (column capacity, IOx cells; Miltenyi Biotec) according to the manufacturer's rec- Serum-replete CFU-F assay. Details of this assay have been described e1~ewhere.l~ Briefly, STRO-I' cells sorted from BMMNC ( 1 0' to 5 X I O4 cells per milliliter) were plated in 24-well tissue culture dishes (Costar, Cambridge, MA) in alpha modification of Eagle's medium (a-MEM; Flow Laboratories, Irvine, Scotland) supplemented with 20% FCS, L-glutamine (2 mmoUL), and P-mercaptoethanol (5 X IO-' mol&,). Cultures were established in triplicate and incubated at 37°C in 5% CO, in air for 14 days. On day 14 of culture, the cells were washed twice with warm RPMI-1640 and then fixed for 20 minutes in I % paraformaldehyde in PBS. Once fixed, the cultures were stained with 0.1% toluidine blue (in 1 % paraformaldehyde) for 1 hour and then rinsed in tap water. Aggregates of 50 cells or more were scored as CFU-F using an Olympus SZ-PT dissecting light microscope (Olympus Optical CO Ltd, Tokyo, Japan). Colony size was also determined by measuring the diameter (mm) of day-l4 CFU-F using a graded monocular eyepiece and a standard graticule.
Serum-deprived CFU-F assay (SDM).
This method is a modification of the SDM developed for the growth of hematopoietic progenitor cells and was adapted for the growth of C m -F . STRO-I' cells sorted from BMMNC (I O4 to 5 X lo4 cells per milliliter) were plated in a-MEM supplemented with 10 pg/mL bovine pancreasderived insulin (Sigma), 2% BSA, 4 pg/mL human low-density lipoprotein (LDL; Sigma, L121 139), 200 pg/mL iron-saturated human transferrin, 2 mmoUL L-glutamine, dexamethasone sodium phosphate deprived conditions were maintained as described above for serumreplete cultures. On day 14, cultures were terminated, and CFU-F colonies were fixed, stained, and scored according to the previously described criteria.
Immunojuoresence staining of CFU-F. To investigate expression of growth factor receptors on the stromal cell progeny of C m -F, colonies at day 14 of assay were stained in situ by indirect immunofluorescence using a number of the anti-growth factor receptor MoAbs listed above. Before immunostaining, cultures were washed three times with cold medium and then incubated with appropriate dilutions of anti-receptor or isotype control MoAb in RPMI-1640 containing 1% BSA for 45 minutes on ice. After washing three times in cold HBSS/5% FCS, second layer antibody (goat anti-mouse IgG-FITC; Southern Biotechnology Associates) diluted 1/50 in the same buffer was applied for a further 45 minutes on ice. The cells were then washed as above and fixed in 2% paraformaldehyde in PBS for 15 minutes, after which time they were briefly washed and mounted in aqueous mountant (Uvinert; BDH, Poole, UK). The labeled specimens were examined using an Olympus BH2-RFCA fluorescence microscope.
Statistical analysis. Analysis of variance (ANOVA) was used to determine differences in CFU-F colony numbers and in colony size between the different groups of cytokine combinations and the control cultures with serum. The level of statistical difference be-931 tween the groups was estimated by the Fisher limited significance difference (FLSD) test at P S .05. The paired t test was also used to determine any differences (at P S .05) in the mean number of CFU-F colonies over a range of plating concentrations between the serum-containing and serum-deprived cultures.
RESULTS
Isolation of CFU-F by MACS using the MoAb STRO-I.
We have previously shown that the IgM monoclonal antibody STRO-1 identifies essentially 100% of clonogenic CFU-F in aspirates of normal human adult bone In the current study, STRO-1' cells represented a mean of 7% 2 0.9% (n = 14) of BMMNC samples analyzed. To obtain sufficient STRO-1' cells from these samples to perform the studies described herein, cell separation by MACSz9 was used. MACS was reproducibly able to give high purity and recovery of STRO-l+ cells and CFU-F. A representative experiment is shown in Fig 1. For all samples of STRO-1' cells obtained by MACS, the mean purity of the preparations was 53.7% t 2.9%, and the recovery of STRO-1' cells in the positive fraction was 51.6% 2 7.8%. STRO-l' and STRO-1 ~ fractions were assayed for content of CFU-F (Table l). CFU-F were not detectable in the STRO-l-, population and there was a ninefold increase in the incidence of CFU-F in the STRO-l+ population compared with their incidence in unseparated BMMNC, with an overall recovery of CFU-F in the positive fraction of 67% -+ 11.2%. These data compare favorably with those previously obtained by FACS.9 Experimental data presented hereafter were derived from experiments performed with STRO-l+ cells isolated by MACS.
Establishment of a clonogenic assay for CFU-F under serum-deprived conditions: A role for glucocorticoids and ascorbate. In initial experiments, STRO-l+ cells were plated in SDM comprising a-MEM supplemented with insulin, transferrin, BSA, and human LDL as a lipid source. In all experiments, culture plates were coated with fibronectin to promote the attachment of stromal progenitor cells in the absence of FCS. Based on previous s t~d i e s ,~~~~~ a combination of EGF, PDGF, IGF-1, and bFGF (each at 10 ng/mL) was added to provide a likely stimulus for colony growth. Under these conditions, however, development of CFU-F colonies did not occur (Fig 2) . Addition of the glucocorticoid DEX at lo-' m o m similarly did not stimulate colony growth. When added to the SDM at a concentration of 100 pmoVL, ASC-2P, a long-acting derivitive of L-ascorbate, initiated CFU-F colony growth to a level approximately IS% of that obtained with the same cell population plated in parallel in medium supplemented with 2 0 8 FCS. However, when both DEX and ASC-2P were added. the number of CFU-Fcolonies obtained was not significantly different from that observed in the FCS-stimulated control cultures (Fig  2) . Importantly, CFU-F growth did not occur in cultures established in SDM/DEX/ASC-2P alone but was absolutely dependent on an exogenous source of growth factors (Fig  2) .
Contribution of EGF, PDGF. IGF-I. and hFGF to CFU-F growth under serum-deprivecl conditions. We next investigated which of the four growth factors used in the initial experiments (EGF, PDGF, IGF-I, and bFGF) are responsible for supporting colony growth under serum-deprived conditions. The factors were added at a concentration of I O ng/ mL, alone and in each of the possible two-and three-factor combinations. As shown in Fig 3A, the clonogenic growth of CFU-F occurred only in response to EGF or PDGF. bFGF, either alone or in the presence of heparin at SO pg/mL, did not stimulate colony growth over a concentration range of 1 to 100 ng/mL (data not shown). IGF-I over the same concentration range was similarly without activity in this assay, regardless of whether insulin was included or omitted from the SDM (data not shown).
EGF and PDGF, either as single factors or in combination, stimulated the development of equivalent numbers of CFU-F colonies (Fig 3A) . Average colony size was, however, much increased in cultures stimulated with the combination of the two factors compared with either factor alone ( P S .OS; Figs 3B and 4) . There was no statistically significant difference between the number of CFU-F colonies stimulated by EGF or PDGF (alone or in combination) under serumdeprived assay conditions and the numbers elicited under serum-replete conditions with 20% FCS. There was, nevertheless, a significant increase in average colony size when CFU-F growth in SDM supplemented with EGF and PDGF was compared with that in 20% FCS ( P S .OS). In contrast with the additive interaction between EGF and PDGF. analysis of CFU-F colony growth in response to each of the other possible combinations between the four growth factors did not reveal statistically significant differences in either colony number or size stimulated by combinations of factors involving EGF and/or PDGF with IGF-I and/or bFGF (Fig 3) .
Collectively, these data demonstrate that the major stimuli for CFU-F growth under serum-deprived conditions arc EGF and PDGF. To optimize growth conditions, dose responses were calculated for both factors. As shown in Fig S. plateau growth of CFU-F in response to EGF and to PDGF occurred over the range I to 100 ng/mL. Half-maximal colony formation in response to either factor occurred at approxirnatcly 0.2 ng/mL. Maximal colony size was attained a t concentrations of either factor in excess of IO ng/mL, and for this reason subsequent experiments were performed (except where stated) using EGF and PDGF at a concentration of I O ng/mL.
To investigate the effect of the interaction between EGF For and PDGF on CFU-F colony size, CFU-F assays were performed in which STRO-I' cells were plated at the optimal concentration of either factor ( I O ng/mL) with the second factor titrated in over the concentration range of 0.01 to 100 ng/mL. The assays were then scored with regard to colony number (Fig 6A and B) and size (Fig 6C and D) based on a comparison with the mean colony sizes obtained with EGF and PDGF alone at the IO ng/mL concentration. Consistent with our previous observations, CFU-F colony number did not change in response to the addition of EGF and PDGF (Fig 6A and B) , but colony size was increased in a dosedependent manner (Fig 6C and D) . Maximum colony diameters were attained at concentrations of EGF or PDGF in excess of 1 ng/mL when added to cultures stimulated with the reciprocal factor at 10 ng/mL.
Having established and optimized culture conditions for assay of CFU-F under serum-deprived conditions, we next compared the plating efficiency of CFU-F in the serumreplete and serum-deprived assays. Based on the data in Fig  6 , the serum-deprived assay was performed using a combination of EGF and PDGF, both at 10 ng/mL. A representative experiment is shown in Fig 7. Both assays demonstrated a linear relationship between the number of cells plated and the number of colonies formed, but the plating efficiency of CFU-F in SDM was significantly higher than in FCS at all cell concentrations examined ( P S .05), particularly at lower cell inocula.
CFU-F express cell suflace receptors for EGF, PDGF,
100
i ' and IGF-l. Previous studies have demonstrated that various cultured stromal cell types express functional receptors for both PDGF and EGF."','' Expression of these receptors by primary clonogenic stromal precursor cells (CFU-F) in fresh aspirates of bone marrow has not been demonstrated. It is possible, therefore, that CFU-F in vivo do not constitutively express receptors for EGF or PDGF and that their response to these factors in vitro, even under the serumdeprived culture conditions used here, represents a culture epiphenomenon in part due to the induction of these receptors. In addition, lack of response to a given factor may represent absence of the appropriate receptor on CFU-F, failure to induce the receptor, or inappropriate downregulation of the receptor in vitro.
To address these issues, FACS was used to directly examine the expression of receptors for EGF, PDGF, and IGF-I on CFU-F isolated from freshly prepared BMMNC. The BMMNC were stained by two-color indirect immunofluorescence with STRO-l in combination with MoAbs to the EGF-receptor (EGF'), PDGF" m-chain, and IGF-1 ' . Representative flow cytometric staining profiles are shown (Fig  8A) . Given previous data demonstrating expression of STRO-1 by essentially a l l CFU-F, the BMMNC samples were sorted into STRO-l '/receptor+ and STRO-1 '/receptor- investigated the response of CFU-F to a broad range of growth factors. For these experiments, each of the growth factors was added at a single concentration at or above the dose determined in previous studies to have optimal activity in clonogenic assays of hematopoietic progenitors. Of a total of 25 purified recombinant growth factors assayed, only five demonstrated any capacity to stimulate CFU-F growth in SDM: EGF, PDGF, IFNy, TNFa, and L 1 (Fig 9) . Clonogenic growth was poor in response to IFNy, TNFa, and ILl , with colony numbers approximately 19%, 5%, and 4%, respectively, of those stimulated in control, serum-replete cultures. Three factors, LIF, IL-6, and L -1 1, only stimulated the development of small (10 to 20 cell) clusters of stromal cells. A number of the above growth factors have been shown in assays of hematopoietic progenitors to have no intrinsic colony-stimulating activity when added as single factors. However, in combination with other growth factors, cytokines such as IL-1 and SCF demonstrate potent synergistic Therefore, we performed a series of experiments in which the activity of each of the above factors was assessed by plating STRO-l+ cells in SDM supplemented with EGF and PDGF at 0.03 ng/mL. This concentration was based on the dose response of each factor (Fig 5) and represented the lowest concentration of either factor with activity in the assay. At this threshold dose of EGFPDGF, we were still unable to demonstrate any CFU-F colonystimulating potential of these factors, including IGF-l and bFGF (data not shown).
Notably, two factors, E-4 and IFNa, demonstrated inhibition of CFU-F colony formation (Fig 10) . This was confirmed by experiments in which each factor was titrated into the assay with EGF and PDGF at the optimum concentration of 10 ng/mL (Fig 10) . Other growth factors with inhibitory activity on primitive hematopoietic progenitors (TGFP and M P -l a ) were assayed in an identical fashion but did not inhibit the in vitro growth of CFU-F (data not shown). subpopulations. Each cell fraction was then assayed for CFU-F content under serum-replete conditions. The data from three experiments demonstrated that a high proportion (consistently greater than 90%) of CFU-F were recovered in the minor STRO-l+/receptor+ subpopulation (Fig 8B) , indicating constitutive expression of all three growth factor receptors by CFU-F. In parallel experiments, BMMNC were double-stained with STRO-1 and MoAbs to other receptor tyrosine kinases, c-kit and c-@S. In these cases, no expression of either receptor could be detected on CFU-F (data not shown). Cattoretti et a13* previously demonstrated expression of NGFR on bone marrow reticular cells in vivo. In accord with that finding, two-color staining with STRO-1 and antibody to NGFR demonstrated a minor subpopulation of STRO-l+ cells coexpressing NGFR, which after cell sorting and in vitro culture, contained virtually all assayable CFU-F (Fig 8B) .
To investigate the possibility of inappropriate receptor downmodulation as a consequence of in vitro culture conditions, CFU-F assayed in serum-replete medium and in SDM supplemented with EGF and PDGF were stained in situ at day 14 of culture by indirect immunofluorescence using antibodies to the above receptors. Expression of EGFR, PDGFR a-chain, IGF-lR, and NGFR was maintained in culture on the progeny of the CFU-F, while c-kit and c-fms remained undetectable (data not shown).
Clonogenic growth of CFU-F does not occur in response to a wide variety of cytokines and growth factors. Given the complete dependence on an exogenous source of cytokines in this serum-deprived CFU-F assay (Fig 2) , we next
DISCUSSION
We have examined the response of bone marrow-derived CFU-F to a variety of cytokines and growth factors in vitro under defined, serum-deprived conditions. All assays were established using a purified, phenotypically defined population of BMMNC expressing the STRO-1 antigen. In a previous report we have shown that this minor population of BMMNC contains all detectable CFU-F as measured under standard serum-containing condition^.^ Importantly, the STRO-1 antibody shows no detectable binding to monocytes or T l y m p h~y t e s ,~ accessory cell populations that may affect positively or negatively the response of CFU-F in unfractionated BMMNC preparations to exogenously added factors. In this regard, previous studies of CFU-F growth factor responsiveness in human and rodent systems have, in virtually all instances, performed assays using whole bone marrow or passaged marrow stromal ~e l l s .~~~*~~" Moreover, these studies were performed in medium supplemented with FCS. A major source of the mitogenic activity of serum is contributed by factors such as EGF and PDGF,35 which together with other possibly inhibitory activities may alter or otherwise mask the response of CFU-F to purified growth factors added to the cultures. For this reason, it was necessary to establish in vitro culture conditions for clonogenic assay of CFU-F in the absence of FCS. A serum-deprived assay was developed that demonstrated absolute dependence on an exogenous source of growth factors for colony growth. The glucocorticoid DEX and a source of ascorbate were found to be critical compo- nents of the SDM. Previous studies analyzing the growth requirements of diploid human fibroblasts in serum-free culture have documented a requirement for glucocorticoid.'s.3" Hydrocortisone has been found to be an important ingredient in long-term marrow culture^,^'^^^ although the precise role of steroid in this system remains to be determined. CFU-F colonies assayed from rabbit bone marrow were shown to increase in number in the presence of hydrocortisone," alFor personal use only. on October 30, 2017. by guest www.bloodjournal.org From Previous reports have documented responsiveness of marrow stromal cells to these mitogens.'*"' In these studies, assays were performed using either unfractionated BMMNC preparations or serially passaged stromal cells plated in the presence of serum, conditions that therefore complicate interpretation of the data. In vivo, more than 90% of CFU-F are non~ycling'~.~""" but rapidly begin to proliferate in vitro when cultured in serum-containing medium."' A recent report that examined the growth regulation of human diploid fibroblasts in a serum-free, chemically defined system similar to the one reported here, demonstrated that EGF and PDGF affect similar cell kinetic parameters, regulating the proportion of cells capable of entering the cell cycle from the quiescent state..'" The investigators reported little effect of these mitogens on the transition of the cells from G, into S phase and, therefore, proposed that EGF and PDGF, acting at early G, restriction points, regulate the activation of diploid human fibroblasts from quiescence.
Based on the data in the current report, EGF and PDGF may play a similar role in triggering the cycling of CFU-F. Very comparable numbers of colonies were initiated by the two factors alone or when added in combination, suggesting a functional redundancy in the regulation of cycling of CFU-F. Consistent with this, studies using fibroblast cell lines have shown that PDGF and EGF both stimulate the expression of c-fos, c-my, and other early G, genes?'.'" show a similar time dependence of induction of commitment to DNA synthesis,?" and result in phosphorylation at tyrosine residues of a similar array of intracellular proteins.?' Thus, a common intracellular pathway for PDGF and EGF signal processing has been proposed.5" Although EGF and PDGF in combination did not stimulate increases in total colony number, colony size was significantly enhanced. Similar observations were reported by Kimura et al."' The mechanism underlying the interaction between these two factors remains to be determined but is clearly of importance given the large increase in cell number that results from culture in the presence of both factors. Our observations are all the more intriguing given the data from studies in other systems that demonstrate decreased cycling in response to a combination of EGF and PDGF.'".' ' It is unlikely that the data presented here are explained by receptor modulation, as it has been reported that PDGF can downregulate EGFR expression" or receptor affinity,?' although the converse is not true.'.' IGF-1 in our system was unable to support colony formation by CFU-F at any concentration over a 3-log dose range, even in SDM lacking insulin, which at supraphysiologic concentrations can compete with IGF-I for receptor binding. This lack of response to IGF-I is not due to the absence of IGF-lR on stromal precursors, which were shown to be constitutively expressed by CFU-F and to be maintained on their progeny in vitro. In serum-replete cultures, failure to respond to IGF-1 may be explained by the presence of serum IGF-binding protein^.'^ It is conceivable that trace amounts of these proteins may be in the BSA used in our serumdeprived culture system. However, the recombinant form of IGF-1 used in our studies lacks the region of the molecule that interacts with the binding proteins" and, thus, cannot be inactivated even if binding proteins were present. An alternative explanation for our results is that CFU-F produce IGF-1 themselves, thereby negating the effects of exogenously added factor. In accord with this, human fibroblasts GRONTHOS AND SIMMONS have been shown to secrete IGF-1 into the culture medium con~titutively~~ and in response to PDGF.s7 Moreover, marrow stromal cells have been demonstrated to produce IGFl,58 and we are currently investigating whether IGF-1 is being produced endogenously in our serum-deprived culture system. Therefore, we cannot at this time preclude a role for IGF-1 in regulating CFU-F growth in this serum-deprived assay. The potential importance of IGF-1 is suggested by data from other studies performed under serum-free conditions in which IGF-1 has been shown to regulate the rate of exit from G, into S phase in human diploid fibroblasts without affecting the cycling fracti01-1,~~ implying a mode of interdependence between IGF-1 and EGFPDGF in regulating activation and cell cycle progre~sion.'~ Basic FGF similarly did not stimulate CFU-F growth under the serum-deprived conditions described in this report. The expression by CFU-F of receptors for bFGF was not examined in the current study but clearly warrants investigation. In order to bind to its receptor and produce a biologic response, bFGF needs to complex with a sulphated proteoglycan such as
The addition of heparin, however, did not elicit colony formation in SDM supplemented with bFGF alone or added in combination with a suboptimal concentration of PDGF and EGF. Using unfractionated mouse bone marrow cell preparations, Wang et alZ7 demonstrated augmentation of CFU-F colony growth in response to bFGF only in the presence of high concentrations of FCS. At low FCS concentrations, bFGF did not show activity, even in the presence of PDGF, suggesting that FCS may contain an activity(ies) (other than PDGF) that synergizes with bFGF and that is unlikely to be present in the SDM conditions used here. Another possible explanation for the failure of bFGF to stimulate colony growth in culture system may, as in the case of IGF-1, be due to possible autocrine production of the factor by stromal cells themselves.6236'
With the development of a factor-dependent, serum-deprived assay for CFU-F, we examined an additional 21 recombinant cytokines for their ability, as single factors, to initiate colony formation. Only three cytokines, IL-lP, TNFa, and IFN-y, demonstrated a minor stimulatory activity. Caution should, however, be exercised in interpreting these data. Primitive hematopoietic progenitors require multiple growth factors to initiate proliferation and development, some of which (eg, IL-l and L-6) have no direct colonystimulating activity but act in synergism with other factors."" By analogy, therefore, it remains possible that a number of the growth factors examined in this study that failed to promote the growth of stromal progenitors as single factors could, when added in appropriate combinations, demonstrate stimulatory activity. A more detailed examination ofthe response of CFU-F to combinations of multiple growth factors will be required to address this point.
Notably, IFNa and 1L-4 were found to be potent inhibitors of CFU-F colony formation stimulated by the EGFPDGF combination at optimal concentration. The inhibition effected by IFNa is in accord with previous but this effect of IL-4 on CFU-F growth has not previously been reported. High affinity receptors for IL-4 have been demonstrated on cloned murine bone marrow stromal cell lines.68
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In addition, L-4 has been shown to upregulate the expression of the vascular cell adhesion molecule-1 (VCA" 1) on human marrow stromal ~e l l s . 6~ By contrast, TGFP and MPla, well-documented inhibitors of hematopoietic progenitor cell pr~liferation~~*" showed no inhibitory activity on CFU-F colony formation.
In conclusion, we have developed a simple, reproducible, serum-deprived clonogenic assay for CFU-F that has allowed us to stringently examine the growth requirements of these stromal progenitors in vitro. Our data demonstrate the lack of response of CFU-F to a wide range of factors active on hematopoietic progenitors and, conversely, the very specific stimulatory effects of EGF and PDGF on these stromal cell precursors. These experiments represent an essential prerequisite for future studies of the role of cytokines in the regulation of stromal cell proliferation, differentiation, and development. These data also have implications for the pathogenesis and possible treatment of conditions of altered stromal cell growth, such as marrow myelofibrosis.
